Table 1.
Characteristics of Rheumatologists Responding to Treat-To-Target Survey (n=439)
| Physicians Who Measure Quantitatively (n=255) |
Physicians Who Do Not Measure Quantitatively (n=184) |
P value | |
|---|---|---|---|
| Physician Characteristics and Practice Patterns | |||
| Age, years | 56.7 (9.8) | 57.8 (9.9) | 0.20 |
| Male, % | 73 | 72 | 0.85 |
| Practice Setting | |||
| Academic | 24 | 23 | 0.005 |
| Solo practice | 18 | 28 | |
| Rheumatology group | 29 | 15 | |
| Multispecialty group | 22 | 20 | |
| Other | 11 | 10 | |
| >20 RA patients seen per week, % | 60 | 54 | 0.20 |
| Years in rheumatologic practice | |||
| ≤20 | 35 | 33 | 0.54 |
| 21–30 | 36 | 33 | |
| >30 | 30 | 35 | |
| Use TNF inhibitors for at least 50% of RA patients, % | 76 | 66 | 0.02 |
| How many TNF inhibitors must a patient fail before you choose another mechanism of action (MOA)?, % | |||
| Exactly 1 | 31 | 26 | 0.22 |
| 2 | 65 | 73 | |
| 3+ | 1 | 2 | |
| None; Non-TNF MOA biologics are my first line | 1 | 2 | |
| Beliefs about Treat-To-Target and RA Patient Outcomes | |||
| Doesn’t believe in “Treat to Target Hype”, % | 14 | 42 | <0.01 |
| What fraction of your RA patients achieve remission?, % | |||
| <20 | 20 | 17 | 0.90 |
| 20–<30 | 20 | 20 | |
| 30–<50 | 24 | 24 | |
| ≥50 | 37 | 39 | |
| What fraction of your RA patients achieve low disease activity?, % | |||
| <50% | 25 | 22 | 0.73 |
| 50%–<60% | 14 | 13 | |
| 60%–<80% | 32 | 35 | |
| ≥80% | 29 | 31 | |
Some column totals may not sum exactly to 100% due to rounding